Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
- Conditions
- Acute Decompensated Heart Failure (ADHF)
- Interventions
- Drug: Placebo
- Registration Number
- NCT07038356
- Lead Sponsor
- Christian Schulze
- Brief Summary
The goal of this clinical trial is to test the hypothesis that the continuation of empagliflozin during decongestive therapy in the setting of acute decompensated and hospitalized heart failure patients is not inferior compared to therapy cessation during the acute heart failure hospitalization.
Randomized treatment (plus standard medical care) in patients with acute decompensated heart failure is one (1) tablet daily of empagliflozin 10 mg or matching placebo during the in-hospital stay (up to a maximum of 30 days), followed by treatment with empagliflozin 10 mg daily after discharge (but no later than day 31) until day 90.
The primary outcome measure is the combined hierarchical endpoint of all-cause mortality, heart failure hospitalization and worsening renal function at 90 days after admission.
Secondary outcome measures are the effects on urine output, diuretic efficiency, quality-of-life and the need for further administration of diuretics.
Participants will
* Take one tablet of study medication once daily (day 1 to day 90)
* Restrict fluid intake to 1.5 liters of fluid per day and record the daily fluid intake for the study from day 1 to day 6 in the patient diary
* Measure the urine output (day 1 to day 6)
* Fill in Questionnaires (EQ-5D-3L (3-level version of the EuroQol five dimensional descriptive system), KCCQ-12 (Kansas City Cardiomyopathy Questionnaire comprising 12 items)) on day 0 (Baseline), at hospital discharge, and on day 30
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 556
- Patients (age ≥ 18 years) with acute decompensated heart failure (HF) according to clinical assessment on active therapy with a SGLT2 inhibitor
- Brain Natriuretic Peptide (BNP) >100 pg/ml or N-terminal pro-BNP (NTproBNP) >300 pg/ml
- Written informed consent obtained
- Negative pregnancy test for women of childbearing potential
- Type 1 diabetes mellitus
- Chronic Kidney Disease (CKD) with eGFR<20 ml/min, or end-stage renal failure with the need for chronic dialysis treatment
- Acute kidney injury (AKI) requiring dialysis treatment
- Known intolerance to empagliflozin
- Acute heart failure without signs of congestion ("dry" patient)
- Indication for coronary angiography or any foreseeable administration of a contrast media
- Need for hemofiltration or any other form of extracorporeal therapy
- Planned surgery
- Previous participation in this trial or recent participation in another clinical trial (within the last 4 weeks before inclusion)
- Identification of any causes of heart failure leading to decompensation that needs urgent management (like acute coronary syndrome, severe unstable arrhythmias, mechanical causes, acute pulmonary embolism)
- Incapacity to understand and / or to provide written informed consent
- Obvious uncontrolled substance abuse
- Pregnancy, breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description control Placebo Randomized treatment with placebo (one tablet) daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90. intervention Empagliflozin 10 MG Oral Tablet [Jardiance] Drug: Empagliflozin (10 mg/day), film-coated tablet Randomized treatment with 10 mg empagliflozin (Jardiance, one tablet) or placebo daily from day 1 until the day of hospital discharge, but no longer than 30 days, followed by 10 mg empagliflozin (Jardiance, one tablet) daily until day 90
- Primary Outcome Measures
Name Time Method Four-step hierarchical composite primary endpoint: time to all-cause death (day 90), number of heart failure events per patient (day 90), time to first heart failure event (day 90), eGFR decrease from baseline to day 90 day 90 The study uses a four-step hierarchical composite primary endpoint:
1. time to all-cause death (day 90)
2. number of heart failure events per patient (day 90)
3. time to first heart failure event (day 90)
4. eGFR decrease from baseline to day 90 (with a between-patient threshold defined as ≥5 ml/min/1.73 m²)
- Secondary Outcome Measures
Name Time Method Single parameters of primary endpoint: eGFR decrease from baseline to day 90 (ml/min/1.73 m²) day 90 Single parameters of primary endpoint: number of heart failure events per patient (day 90) day 90 Single parameters of primary endpoint: time to first heart failure event (day 90) day 90 Cardiovascular and total mortality on day 90 day 90 Number of patients alive and without re-hospitalization on day 90 day 90 Re-hospitalization after initial discharge, including reason: time to first rehospitalization after discharge day 90 Re-hospitalization after initial discharge, including reason: numbers of re-hospitalizations day 90 Number of patients with a decrease in eGFR of 5 ml/min/1.73 m² or more from baseline to day 90 day 90 Daily and cumulative urine output (UOP, ml) measured from day 1 until day 6 day 1 until day 6 Diuretic efficiency (ml urine per mg furosemide equivalent) from day 1 to day 6 day 1 until day 6 Change in body weight from baseline to day 1, day 3, day 6, discharge (supposed between day 6-10), day 30, and day 90 day 1, day 3, day 6, discharge (supposed between day 6-10), day 30, and day 90 Renal function at baseline, day 3, day 6, day 30, and day 90 baseline, day 3, day 6, day 30, and day 90 * Decrease in eGFR of \>20 ml/min/1.73 m2
* Doubling of serum creatinine
* Need for renal replacement therapy
* Total urinary sodium excretion and fractional excretion of sodiumLiver function: bilirubin (nmol/ml) at baseline, day 3, day 6, day 30, and day 90 baseline, day 3, day 6, day 30, and day 90 Liver function: serum aminotransferases (µmol/l*s) at baseline, day 3, day 6, day 30, and day 90 baseline, day 3, day 6, day 30, and day 90 Liver function: relevant change in coagulation status (Quick/INR, %, 3X upper limit of normal) at baseline, day 3, day 6, day 30, and day 90 baseline, day 3, day 6, day 30, and day 90 Change in NT-proBNP (N-terminal pro Brain natriuretic peptide, pg/ml) (alternatively calculated from BNP, Brain natriuretic peptide, pg/ml) from baseline to day 6, day 30, and day 90 baseline to day 6, day 30, and day 90 Quality of life (EQ-5D-3L questionnaire, 3-level version of the EuroQol five dimensional descriptive system ) on day 0, at hospital discharge (supposed between day 6-10), and on day 30 day 0, at hospital discharge (supposed between day 6-10), and on day 30 Quality of life: EQ-5D-3L questionaire. The EQ-5D-3L questionnaire consists of two parts: part one contains questions about patients mobility, self-care, usual activities, pain/discomfort, anxiety/depression, with scores from 1 (no problem), 2 (some problems), and 3 (extreme problems). Part two measures patients health on a scale from 0 (the worst imaginable health) to 100 (the best imaginable health), on day 0, at hospital discharge (supposed between day 6-10), and on day 30
Severity of heart failure (HF): KCCQ-12 questionnaire (Kansas City Cardiomyopathy Questionnaire comprising 12 items) on day 0, at hospital discharge (supposed between day 6-10), and on day 30 day 0, at hospital discharge (supposed between day 6-10), and on day 30 KCCQ-12 questionnaire: scores range from 0 to 100, with higher scores indicating better health status, on day 0, at hospital discharge (supposed between day 6-10), and on day 30
Intermediate Care Unit (IMC) / Intensive Care Unit (ICU) and hospital length of stay, days until discharge (supposed between day 6-10) discharge (supposed between day 6-10) Single parameters of primary endpoint: time to all-cause death (day 90) day 90
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.